Coates, Laura C.
Rahman, Proton
Mease, Philip J.
Shawi, May
Rampakakis, Emmanouil
Kollmeier, Alexa P.
Xu, Xie L.
Chakravarty, Soumya D.
McInnes, Iain B.
Tam, Lai-Shan
Funding for this research was provided by:
Janssen Global Medical Affairs
Article History
Received: 27 June 2023
Accepted: 18 January 2024
First Online: 4 February 2024
Declarations
:
: The DISCOVER-2 study was conducted in accordance with the principles of the Declaration of Helsinki and International Council for Harmonization Guidelines for Good Clinical Practice. Each site’s governing ethical body approved study protocols, and all patients provided written informed consent, as previously reported [CitationRef removed].
: Not applicable.
: LCC: received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, MoonLake Immunotherapeutics, Novartis, Pfizer, and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Medac, Novartis, Pfizer, and UCB. For manuscripts: LCC is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; meeting attendance/travel support from Janssen; and research grants from Janssen and Novartis. PJM: received research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, SUN, and UCB; consulting fees from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Immagene, Janssen, Novartis, Pfizer, SUN, UCB, Ventyx; speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. MS: Shareholder of Johnson & Johnson. Employee of Janssen Pharmaceutical Companies of Johnson & Johnson. ER: consultant of Janssen. Employee of JSS Medical Research. APK: shareholder of Johnson & Johnson. Employee of Janssen Research & Development, LLC. XLX: shareholder of Johnson & Johnson. Employee of Janssen Research & Development, LLC. SDC: employee of Janssen Scientific Affairs, LLC. Shareholder of Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly-owned subsidiary. IBM: received consultant fees from AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, Cabaletta, Compugen, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB; grant/research support from Amgen, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Roche, and UCB; and is a shareholder for Causeway Therapeutics, and Evelo Compugen. L-ST: consultant of AbbVie, Boehringer Ingelheim, Eli Lilly Janssen, Pfizer, and Sanofi. Grant/research support from Amgen, Boehringer Ingelheim, Janssen, GlaxoSmithKline, Novartis, and Pfizer.